Review article · 2010 · Open access

Second-Generation Antipsychotic Drugs and Extrapyramidal Side Effects: A Systematic Review and Meta-analysis of Head-to-Head Comparisons

Christine Rummel‐Kluge, Katja Komossa, Sandra Schwarz, Heike Hunger, Franziska Schmid, Werner Kissling, John M. Davis, Stefan Leucht

Schizophrenia Bulletin, 38(1), 167–177 · Published 31 May 2010 · DOI 10.1093/schbul/sbq042

Open PDFView at the publisherCite this paper

In brief

“Second-Generation Antipsychotic Drugs and Extrapyramidal Side Effects: A Systematic Review and Meta-analysis of Head-to-Head Comparisons” is a 2010 review article by Christine Rummel‐Kluge and 7 co-authors, published in Schizophrenia Bulletin. OpenAlex counts 300 citations as of 20 November 2026, which puts it in the top 1% of works published in 2010 by citations. It is open access: the full text is free to read at Schizophrenia Bulletin.

Citations
300
Most cited in
2019 (26)
Field-weighted impact
2.62
References
47
Authors
8

Abstract

OBJECTIVE: While all second-generation antipsychotics (SGAs) are promoted for having a low risk of extrapyramidal side effects (EPS), clinical observations suggest differences between the various agents. Nevertheless, this question has never been examined in a systematic review and meta-analysis of head-to-head comparisons. METHODS: We searched the register of the Cochrane schizophrenia group (last search May 2007), supplemented by MEDLINE (last search July 2009) for randomized, blinded studies comparing the following SGAs in the treatment of schizophrenia or related disorders: amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone, and zotepine. At least 3 reviewers extracted the data independently. The primary outcome was "use of antiparkinson medication." The results were combined in a meta-analysis. RESULTS: We included 54 studies with 116 arms. Risperidone was associated with more use of antiparkinson medication than clozapine, olanzapine, quetiapine, and ziprasidone. Ziprasidone showed more use of antiparkinson medication than olanzapine and quetiapine and zotepine more than clozapine. There was no significant difference between amisulpride and its comparators (olanzapine, risperidone, or ziprasidone). Quetiapine showed significantly less use of antiparkinson medication than the 3 other SGAs it was compared with (olanzapine, risperidone, and ziprasidone). Scale-derived data (Barnes Akathisia Scale and Simpson Angus Scale) were limited. CONCLUSIONS: Our meta-analysis demonstrates that there are differences between the SGAs in their ability to induce EPS that clinicians consider warrant treatment with antimuscarinic drugs. Even though the differences were relatively small, they might be important for individual patients and should be taken into account in drug choice.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Rummel‐Kluge, C., Komossa, K., Schwarz, S., Hunger, H., Schmid, F., Kissling, W., Davis, J. M., & Leucht, S. (2010). Second-Generation Antipsychotic Drugs and Extrapyramidal Side Effects: A Systematic Review and Meta-analysis of Head-to-Head Comparisons. Schizophrenia Bulletin, 38(1), 167–177. https://doi.org/10.1093/schbul/sbq042

MLA 9

Rummel‐Kluge, Christine, et al. “Second-Generation Antipsychotic Drugs and Extrapyramidal Side Effects: A Systematic Review and Meta-analysis of Head-to-Head Comparisons.” Schizophrenia Bulletin, vol. 38, no. 1, 2010, pp. 167–177. https://doi.org/10.1093/schbul/sbq042.

Chicago

Rummel‐Kluge, Christine, Katja Komossa, Sandra Schwarz, Heike Hunger, Franziska Schmid, Werner Kissling, John M. Davis, and Stefan Leucht. 2010. “Second-Generation Antipsychotic Drugs and Extrapyramidal Side Effects: A Systematic Review and Meta-analysis of Head-to-Head Comparisons.” Schizophrenia Bulletin 38 (1): 167–177. https://doi.org/10.1093/schbul/sbq042.

Harvard

Rummel‐Kluge, C. et al. (2010) ‘Second-Generation Antipsychotic Drugs and Extrapyramidal Side Effects: A Systematic Review and Meta-analysis of Head-to-Head Comparisons’, Schizophrenia Bulletin, 38(1), pp. 167–177. doi:10.1093/schbul/sbq042.

IEEE

C. Rummel‐Kluge et al., “Second-Generation Antipsychotic Drugs and Extrapyramidal Side Effects: A Systematic Review and Meta-analysis of Head-to-Head Comparisons,” Schizophrenia Bulletin, vol. 38, no. 1, pp. 167–177, 2010, doi: 10.1093/schbul/sbq042.

BibTeX

@article{rummelkluge2010second,
  title     = {{Second-Generation Antipsychotic Drugs and Extrapyramidal Side Effects: A Systematic Review and Meta-analysis of Head-to-Head Comparisons}},
  author    = {Rummel‐Kluge, Christine and Komossa, Katja and Schwarz, Sandra and Hunger, Heike and Schmid, Franziska and Kissling, Werner and Davis, John M. and Leucht, Stefan},
  journal   = {Schizophrenia Bulletin},
  year      = {2010},
  volume    = {38},
  number    = {1},
  pages     = {167--177},
  doi       = {10.1093/schbul/sbq042},
  url       = {https://doi.org/10.1093/schbul/sbq042}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
20172121
20181616
20192626
20201919
20211818
20221818
20231010
20241111
20251414
202699

Its field-weighted citation impact is 2.62: it has been cited 2.62 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment

  • atypical antipsychotics
  • extrapyramidal symptoms

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Rummel‐Kluge, C., Komossa, K., Schwarz, S., Hunger, H., Schmid, F., Kissling, W., Davis, J. M., & Leucht, S. (2010). Second-Generation Antipsychotic Drugs and Extrapyramidal Side Effects: A Systematic Review and Meta-analysis of Head-to-Head Comparisons. Schizophrenia Bulletin, 38(1), 167–177. https://doi.org/10.1093/schbul/sbq042

How many times has this paper been cited?

300 times, according to OpenAlex on 20 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Schizophrenia Bulletin: sign in and open the PDF from this page.

Who wrote this paper?

Christine Rummel‐Kluge, Katja Komossa, Sandra Schwarz, Heike Hunger, Franziska Schmid, Werner Kissling, John M. Davis, Stefan Leucht.

What is the DOI of this paper?

10.1093/schbul/sbq042, permanently at https://doi.org/10.1093/schbul/sbq042. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 20 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.